BlackRock Fund Advisors’s Carisma Therapeutics CARM Stock Holding History

BlackRock Fund Advisors’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5K	Buy	118 +27	+30%	+$1.19K	﹤0.01%	4055
2016 Q3	$5K	Buy	91 +10	+12%	+$745	﹤0.01%	4060
2016 Q2	$3K	Sell	81 -1,453	-95%	-$36.8K	﹤0.01%	4164
2016 Q1	$10K	Sell	1,534 -127	-8%	-$1.76K	﹤0.01%	3977
2015 Q4	$100K	Buy	+1,661	New	+$94.3K	﹤0.01%	3730
2015 Q2	–	Sell	-5,764	Closed	-$1.03M	–	3873
2015 Q1	$1.03M	Sell	5,764 -9	-0.2%	-$1.97K	﹤0.01%	3213
2014 Q4	$1.37M	Buy	5,773 +865	+18%	+$194K	﹤0.01%	3204
2014 Q3	$1.09M	Sell	4,908 -190	-4%	-$45.1K	﹤0.01%	3190
2014 Q2	$1.34M	Sell	5,098 -461	-8%	-$114K	﹤0.01%	3148
2014 Q1	$1.8M	Buy	+5,559	New	+$1.66M	﹤0.01%	3148

Other funds holding CARM

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $107M AUM 37.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock Fund Advisors's CARM Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Carisma Therapeutics (CARM) stake by 30% in Q4 2016, buying an estimated $1.19K and bringing the position to 118 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4055.

BlackRock Fund Advisors first reported a position in CARM in Q1 2014 and has held it in 10 quarters since. The position peaked at $1.8M in Q1 2014. 27 funds tracked by Wall St. Rank hold CARM as of Q4 2016.

BlackRock Fund Advisors held 118 shares of Carisma Therapeutics worth $5K as of Q4 2016.
BlackRock Fund Advisors bought 27 Carisma Therapeutics shares in Q4 2016, an estimated $1.19K.
Carisma Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4055 holding.
BlackRock Fund Advisors first reported a position in Carisma Therapeutics in Q1 2014 and has held it in 10 quarters since.
BlackRock Fund Advisors's Carisma Therapeutics position peaked at $1.8M in Q1 2014.
27 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.